{"schema_version":"secwatch.filing_event.v1","accession":"0001568276-22-000302","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2022-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.245574+00:00","generated_at":"2026-06-27T13:47:08.949244+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tenax Therapeutics appoints Robyn Hunter to Board, cures Nasdaq audit committee compliance","bullets":["Robyn Hunter appointed as independent director and chair of Audit and Compliance Committee, effective Jan 28, 2022.","Hunter is CFO of Fortress Biotech; adds financial and life sciences expertise to the Board.","Appointment resolves non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) for audit committee composition.","Board remains majority independent following her appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001568276-22-000302","json":"https://secwatch.observer/filing/0001568276-22-000302.json","markdown":"https://secwatch.observer/filing/0001568276-22-000302.md","text":"https://secwatch.observer/filing/0001568276-22-000302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000156827622000302/0001568276-22-000302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000156827622000302/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T13:47:08.949244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68b20ac264","claim":"Robyn M. Hunter was appointed as Member of the Board at TENAX THERAPEUTICS, INC..","evidence_excerpt":"On January 26, 2022, the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) appointed Robyn M. Hunter as a member of the Board, effective January 28, 2022, to serve until the Company’s 2022 annual meeting of stockholders or until her successor is duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000156827622000302/0001568276-22-000302-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}